FFAR2 and colitis: Other authors also confirmed this data treating WT mice with an FFAR2 agonist, and they observed a reduction in DSS-induced colitis compared with controls, indicating that FFAR2 activation plays a key role in the protection of intestinal inflammation (Agus et al., 2016).